Data is generated by Thermo Fisher's Ion GeneStudio S5 next-generation sequencing system.
Oncologica develops precision oncology solutions to personalise cancer treatments.
They achieve this by identifying individual genetic biomarkers, and matching individual patient tumours to specific medicines. Oncologica uses the Ion GeneStudio S5 system to run tests and record genomic sequence data.
Arkivum is providing an integrated solution that meets data requirements of Thermo Fisher's Ion GeneStudio S5 system users such as Oncologica.
A secure transfer mechanism migrates sequencing data into the Arkivum platform, where data is safeguarded, indexed, preserved, and made usable according to Oncologica's data policies.
Arkivum Trust makes Oncologica's regulated data discoverable and accessible whenever needed. Ion GeneStudio S5 users are able to search for data managed by Arkivum, share it securely, and re-import for further analysis and experimentation.
As an expanding CRO Oncologica needs to comply with a diverse range of regulatory bodies.
Oncologica was satisfied that Arkivum's international client base meant they are able to manage sensitive data in compliance with world-wide standards and regulatory bodies, such as MHRA GxP Data Integrity Guidance and FDA 21 CFR Part 11, 210 and 211.
Oncologica was particularly reassured by Arkivum's GDPR-compliant processes, as they frequently receive data access requests from patients.
PepGen receives FDA designations for Duchenne muscular dystrophy therapy
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Astellas Pharma's CRESEMBA receives orphan drug and paediatric exclusivity from FDA
SK Biopharmaceuticals' cenobamate achieves 100,000 patient treatment milestone
Calliditas Therapeutics' Nefecon receives additional seven years orphan drug exclusivity from US FDA
Merck finalises acquisition of Harpoon Therapeutics Inc
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Celltrion USA submits CT-P39 Biologics License Application to FDA
iOnctura's first-in-class autotaxin cancer therapy granted US FDA Orphan Drug Designation
Epitomee submits Weight Loss Capsule for FDA approval in US
Calliditas Therapeutics TARPEYO receives seven years orphan drug exclusivity from US FDA
Camurus reports Oclaiz NDA accepted by FDA for acromegaly treatment
TME Pharma plans NOX-A12 Phase 2 trial in brain cancer after FDA IND clearance